Explore published research on synthetic cannabinoids, including study methods and limitations.
A 20-year-old developed dependence on Spice Gold over 8 months, with physical withdrawal including elevated blood pressure (180/90), tachycardia (125 bpm), sweating, and tremor resembling cannabis withdrawal.
Analysis of 140+ herbal incense products from 2008-2009 showed manufacturers rapidly switched synthetic cannabinoid ingredients in response to German bans, making contents unpredictable for consumers.
Review warned that synthetic cannabinoids in "Spice" products were more potent than natural cannabis, showed addiction potential, and posed identification challenges.
Synthetic cannabinoids JWH-018 and JWH-073 produced THC-like effects in monkeys but lasted only 1-2 hours versus THC's 4, potentially increasing addiction risk.
Review of Spice/K2 effects found anxiety and psychosis reports, while three cases showed cannabis-dependent users found synthetics relieved their withdrawal.
Monkeys developed 9.2-fold tolerance to THC but only 3.6-4.3-fold cross-tolerance to higher-efficacy synthetic cannabinoids, consistent with receptor theory.
Six ER patients after Spice use showed tachycardia, seizures, and hallucinations, highlighting that synthetic cannabinoids are more dangerous than natural cannabis.
Two cases of synthetic cannabinoid withdrawal showed anxiety and tachycardia more severe than cannabis withdrawal, with natural THC failing to improve symptoms.
Comprehensive review found synthetic cannabinoids are 2-100x more potent than THC, producing severe adverse effects including psychosis, kidney failure, and cardiac events.
In mice, orexin-1 signaling supported cannabinoid reward. Blocking it reduced self-administration and erased THC-evoked accumbens dopamine.
About 9-10% of participants in a U.S./Mexico border community had tried synthetic cannabinoids or Salvia, with current marijuana use being the strongest predictor.
Swedish monitoring detected over 50 different new psychoactive substances in emergency patients, predominantly young males, with synthetic cannabinoids among many diverse classes.
Review found synthetic cannabinoids are full CB1 agonists with higher potency than THC (a partial agonist), explaining their increased potential for adverse reactions and toxicity.
Case of a 38-year-old man who developed cannabinoid hyperemesis syndrome from K2 synthetic cannabis, diagnosed after extensive negative workup, with symptoms relieved only by hot showers.
Auckland detox services saw 47 synthetic cannabinoid withdrawal presentations in one year, with 20 requiring inpatient care. It became the third largest detox admission category.
Mouse study found synthetic cannabinoid JWH-018 impaired sensory function at very low doses and caused convulsions at high doses, effects not seen with equivalent THC doses.
A clinical review documented the rise of synthetic cannabinoids and other designer drugs, noting unpredictable toxicity, psychosis risk, and evasion of standard drug tests.
Among 100 hospitalized male bipolar patients, current substance use tripled violence risk, with cannabis, alcohol, and synthetic cannabinoids as the most common substances.
Synthetic cannabinoid JWH-018 and two halogenated variants impaired memory in mice more potently than THC, disrupting hippocampal synaptic transmission through CB1 receptors.
A 16-year-old developed a perforated duodenal ulcer after 3 years of synthetic cannabinoid use, requiring emergency surgery with successful recovery.
Novel synthetic cannabinoids AKB48 and 5F-AKB48 caused seizures, aggression, sensory impairment, and dopamine release in mice, with the fluorinated version being more potent.
Synthetic cannabinoid dependence and withdrawal are underrecognized problems with no established treatment, though benzodiazepines and quetiapine may provide some relief.
Four third-generation Spice/K2 compounds showed CB1 binding up to 30x higher than JWH-018, with potent dopamine release in the brain's reward center.
The Spice compound AM2201 was found to be 14 times more potent than THC with a rapid onset and short 60-minute half-life, helping explain the severe adverse effects seen with synthetic cannabinoid products.
A year-long systematic study of drug-related ER visits in a Swiss hospital found cannabis was the most commonly detected substance (33%), though novel psychoactive substances were rarely involved.
International survey data shows synthetic cannabinoid use affects 0.2-4% of the population, peaks in late teens, is mostly experimental and curiosity-driven, with users overestimating how common it is.
Animal study shows two synthetic cannabinoids found in "spice" products produce dangerous effects even at individually sub-threshold doses when combined, suggesting synergistic toxicity.
Survey of 848 NZ police detainees found 20% of synthetic cannabinoid users reduced or stopped natural cannabis use, suggesting modest substitution, though SC users had higher baseline cannabis consumption overall.
Survey of 105 frequent legal high users in Auckland found 58% of synthetic cannabinoid users met dependence criteria, with common reports of insomnia (29%), nausea (25%), and anxiety (21%).
Adolescent cannabinoid exposure in mice altered cocaine withdrawal in adulthood, preventing anxiety but worsening depressive symptoms during cocaine cessation.
Three new synthetic cannabinoids showed nanomolar potency and caused seizures, aggression, and neurotoxicity in mice, confirming their much greater danger compared to natural cannabis.
Synthetic cannabinoid users showed significantly worse executive function, memory, and mental health compared to both recreational cannabis users and non-users across two countries.
Turkish versions of the CUPIT and CPQ cannabis screening tools showed good reliability and validity for both cannabis and synthetic cannabinoid use disorder patients.
Quantitative pharmacological analysis confirmed that five synthetic cannabinoids produce their core effects through CB1 receptors, just like THC, rather than through non-CB1 targets.
Brain slice study showing JWH-018 was 47 times more potent than THC at disrupting hippocampal synaptic transmission, with all synthetic cannabinoids tested impairing memory-related brain plasticity.
Review consolidating behavioral research on synthetic cannabinoids, finding evidence for abuse potential, tolerance, dependence, and toxicity that often exceeds THC, with significant knowledge gaps remaining.
Review explaining that synthetic cannabinoids are full agonists with higher binding affinity than THC (a partial agonist), producing more intense effects and more severe neurological and cardiovascular complications.
Prospective study found that opioid-dependent patients who also used synthetic cannabinoids experienced significantly longer withdrawal and craving during detoxification.
Mouse study demonstrated that a CB1 receptor antagonist rapidly reversed synthetic cannabinoid intoxication effects, supporting the concept of a cannabinoid overdose antidote.
Rat study found synthetic cannabinoids lower temperature through CB1 receptors but raise blood pressure through a separate sympathetic nervous system mechanism unrelated to cannabinoid receptors.
Review finding synthetic cannabinoids are more potent, more dangerous, and more psychiatrically harmful than natural cannabis, with rapid chemical evolution evading regulation.
Review of 98 reported cases found cannabinoid-related strokes mainly affected young male chronic users, with reversible vasoconstriction as a proposed mechanism in 27% of cases.
Adolescent synthetic cannabinoid exposure triggered schizophrenia-like dopamine changes in genetically susceptible rats but not in non-susceptible rats, modeling the human gene-environment interaction.
Veterinary review documents rising pet exposures to marijuana, CBD, and synthetic cannabinoids, with dogs especially sensitive to THC due to higher cerebellar CB1 receptor density.
Online school program reduced teenagers' intentions to use synthetic cannabis by 2 years, with controls 3.5x more likely to intend use, but only when all 4 lessons were completed.
Review finds synthetic cannabinoids bind brain receptors with much higher potency than natural cannabis, causing psychosis, kidney failure, cardiac problems, and death.
Review found synthetic cannabinoids trigger new-onset psychosis and relapses, with effects more complex and potentially more severe than natural cannabis due to full agonist pharmacology.
Study of 44 ED patients found third-generation synthetic cannabinoids (AB-CHMINACA, MDMB-CHMICA) caused severe poisoning in 20%, seizures in 27%, and prolonged symptoms in 34%, exceeding earlier generation toxicity.
Systematic review found synthetic cannabinoids in 10-13% of acute psychiatric patients, associated with higher psychotic symptoms than natural cannabis, and capable of triggering new-onset psychosis.
Review of 13 synthetic cannabinoids found they are processed by and inhibit multiple drug-metabolizing enzymes, creating potential for dangerous drug-drug interactions in polysubstance users.
First neuroimaging study of synthetic cannabinoid users found reduced gray matter volume across multiple brain regions and impaired neural activity during working memory tasks.
Case report documented driving impairment from synthetic cannabinoid 5F-ADB, detected at 26.37 ng/mL in blood with no other drugs present. One of the first cases conclusively linking synthetic cannabinoids to impaired driving.
A young woman had an acute heart attack (anterior STEMI) shortly after using synthetic cannabis, highlighting the serious cardiovascular risks of these potent compounds.
Comprehensive ED guide covers cannabinoid pathophysiology, differences between natural and synthetic products, and emerging treatments for cannabinoid hyperemesis including haloperidol and capsaicin.
A review of synthetic cannabinoid toxicities documented severe effects across multiple organ systems including cardiac arrest, psychosis, seizures, and kidney failure, plus deaths from contaminated products.
Adolescents in the ED after synthetic cannabinoid use had 3.4x higher odds of coma and 3.9x higher odds of seizures than those using traditional cannabis, showing a distinct and more dangerous toxicity profile.
A case of cardiac tamponade in a synthetic cannabinoid user adds to the evidence of serious cardiovascular toxicity from these substances, which can cause a wide range of heart complications.
Six synthetic cannabinoid users developed multiple organ failure including severe muscle breakdown, kidney failure, and the first reported case of SC-associated liver failure requiring transplantation.
A 25-year-old developed delayed brain hemorrhage days after synthetic cannabinoid use, despite an initially normal brain CT, highlighting the risk of late intracranial complications.
A 16-patient cohort with bleeding from rat poison-contaminated synthetic cannabinoids showed 75% had severely abnormal clotting, one died, and treatment averaged $5,300 per hospitalization.
AKB48 stimulated dopamine reward pathways at low doses but caused hypothermia, catalepsy, and cardiac depression at higher doses, with all effects mediated through CB1 receptors.
A synthetic marijuana user developed severe blood clotting failure and cardiac arrest from brodifacoum (rat poison) contamination, adding to evidence of a contamination crisis.
Adolescent synthetic cannabinoid users had thinner frontal cortex than controls, with ADHD comorbidity producing additional brain changes, suggesting interactive effects on the developing brain.
Retrospective study of 1,661 psychiatric inpatients found synthetic cannabinoid users didn't have longer stays or need higher antipsychotic doses than cannabis users, while both groups had shorter stays than non-drug users.
Clinical review for psychiatrists finds synthetic cannabinoids cause faster dependence, worse psychiatric symptoms, more dangerous withdrawal, and physical effects including seizures and death compared to natural cannabis.
Mouse study maps synthetic cannabinoid 5F-AMB's effects: anxiety reduction and memory impairment via CB1 receptors in different brain regions, with severe locomotor impairment at systemic doses.
CUMYL-4CN-BINACA caused seizures in mice at the lowest dose reported for any synthetic cannabinoid, acting through CB1 receptors.
JWH-018 impaired memory by elevating brain endocannabinoids (suppressing FAAH and MAGL) and reducing BDNF, with all effects reversible by CB1 receptor blockade.
Survey of 1,140 college students found 7.9% used synthetic cannabinoids, driven by legality and drug test avoidance, with natural cannabis users at 7.6x higher odds.
Systematic review of cannabis for PTSD through 2019 found promising signals for nabilone and nightmares, but most evidence remained low-quality and the broader case unproven.
Controlled study found the synthetic cannabinoid JWH-018 impaired memory and tracking in all users, with dissociation and amnesia in those who got the strongest high.
Large European ER dataset found synthetic cannabinoids nearly tripled seizure risk while natural cannabis was associated with lower seizure odds.
Lab study found synthetic cannabinoids and THC all triggered programmed cell death in human placental cells, with synthetics being more potent than THC.
Review covers the 190+ synthetic cannabinoids reported in Europe, explaining why they are more potent and dangerous than natural cannabis as full receptor agonists.
Analysis of 1,660 online posts revealed detailed user experiences with synthetic cannabinoids, providing insights into motivations, effects, and toxicity.
Study of 49 confirmed synthetic cannabinoid patients found concomitant drug use in 69.4%, with significantly worse outcomes than synthetic cannabinoid use alone.
Synthetic cannabinoids JWH-073 and AM-2201 caused significantly more seizures in mice than THC, while endogenous cannabinoid analogs caused none, with effects mediated through CB1 receptors.
A study of 128 participants found chronic synthetic cannabinoid users had higher neuroticism, lower agreeableness, and greater schizotypal traits than natural cannabis users or non-users, suggesting SC users may be more psychiatrically vulnerable.
An Australian study of 55 synthetic cannabinoid deaths found acute toxicity was the top cause but cardiovascular disease was strikingly common in these relatively young decedents, with AB-CHMINACA the most frequently detected compound.
The synthetic cannabinoid JWH-018 produced nausea-like behavior in rats through CB1 receptors, with elevated stress hormones, supporting the theory that cannabinoid hyperemesis syndrome involves stress response dysregulation.
Mouse study found synthetic cannabinoids combined with alcohol caused worse motor impairment than either alone, mediated by reduced glutamate signaling in the cerebellum via CB1 receptors.
Lab and animal testing found the synthetic cannabinoid EG-018 has high cannabinoid receptor affinity but behaves as a weak partial agonist, producing limited effects only via intravenous administration.
Study of 119 acutely psychotic patients found cannabinoid users showed an unusual inverse relationship between IL-6 inflammation and psychosis severity, with synthetic cannabinoid users more likely to need emergency sedation.
Systematic review of 34 reports of deaths involving synthetic cannabinoids found no reliable toxic dose ranges could be established, and cause of death often remained unclear.
Study of 40 synthetic cannabinoid users found significantly elevated DNA damage, oxidative stress, and inflammatory markers compared to healthy controls, suggesting measurable biological harm from regular use.
Study of 165 schizophrenia patients found substance use disorder quadrupled self-harm risk, with cannabis and synthetic cannabinoids most commonly abused among those who self-injured.
Case series of 30 ICU admissions from synthetic cannabinoid use found one-third presented in coma, 70% needed intubation, and standard drug tests missed the substance in over half of cases.
Illinois outbreak linked synthetic cannabinoids contaminated with rat poison (brodifacoum) to 174 severe bleeding cases and 5 deaths in 2018.
Study of 592 high-risk drug users found 75.7% substituted drugs, with 33.5% of cannabis users switching to synthetic cannabinoids and 35.9% of heroin users to street methadone.
Among 342 drug treatment patients, cannabis use was the strongest predictor of synthetic cannabinoid use (AOR 9.86), while gabapentinoids predicted prescription opioid use (AOR 14.33).
Analysis of 615 cannabinoid poisonings found synthetic cannabinoids caused more cardiovascular/GI symptoms than cannabis, while medical cannabis cases were milder.
AB-FUBINACA produced classic cannabinoid effects that cleared rapidly from the brain but still induced physical dependence after just 5 days of twice-daily dosing in mice.
THC required both CB1 and CB2 receptors for pain relief and catalepsy, while synthetic cannabinoid XLR11 needed only CB1. GPR55 deletion enhanced cannabinoid responses, suggesting it normally opposes them.
Synthetic cannabinoids (Spice, K2) are far more potent than natural cannabis, with 207 compounds identified in Europe. As full receptor agonists, they cause severe toxicity including renal damage, respiratory depression, and death.
Synthetic cannabinoids (Spice, K2) are full receptor agonists, unlike natural THC, explaining their extreme potency. They cause severe toxicity including heart damage, immune suppression, and death.
In 2018, synthetic cannabinoids contaminated with rat poison anticoagulants caused 174 hospitalizations and 5 deaths in Illinois, the first mass poisoning event of its kind.
New generation synthetic cannabinoids with alkene modifications showed up to 10x the potency of previous compounds and were found in 25 forensic cases including deaths and impaired driving.
Two patients with untreated schizophrenia caused severe eye injuries to themselves while intoxicated on synthetic cannabinoid K2, both hallucinating a bug behind their eye.
Animal study finds the synthetic cannabinoid MMB-Fubinaca produces stronger effects in males than females, all through CB1 receptors.
Study of 124 toxicology patients found 69% of new psychoactive substance cases involved synthetic cannabinoids, with most users primarily seeking to get high rather than avoiding drug tests.
Controlled study found the synthetic cannabinoid JWH-018 at a relatively low dose significantly impaired motor coordination, attention, memory, and response speed in 24 cannabis-experienced adults.
First clinical description of fatal 4F-MDMB-BINACA intoxication: a 22-year-old died of multi-organ failure 11 days after extensively vaping this synthetic cannabinoid.
Five days of synthetic cannabinoid XLR-11 caused pronounced liver necrosis in mice, driven by oxidative stress, inflammation, and cell death pathways.
The deadly synthetic cannabinoid 5F-MDMB-PINACA produces metabolites that remain active at CB1 receptors with atypical pharmacology, potentially explaining its severe toxicity.
Hospital presentations for synthetic cannabinoid poisoning in the UK showed no change after the 2016 Psychoactive Substances Act banned their sale.
A survey of 284 frequent synthetic cannabinoid users found worse withdrawal, faster tolerance, and harder dose control compared to high-potency natural cannabis.
In 71 patients, blood levels of the synthetic cannabinoid 5F-MDMB-PICA followed a dose-response pattern with CB1 receptor activation, and higher activation predicted greater loss of consciousness.
ADB-BUTINACA emerged in 10 UK emergency patients since 2021, causing reduced consciousness in all cases, including two from contaminated edible "cannabis" gummies.
At least 20 new fourth-generation synthetic cannabinoids emerged between 2017-2021 with higher receptor potency and increased adverse reactions including psychosis, self-harm, and deaths.
First study showing adolescent mice voluntarily self-administered synthetic cannabinoid JWH-018, leading to lasting compulsive behaviors and brain neuroinflammation in adulthood.
Swiss drug checking found half of low-THC cannabis samples were laced with synthetic cannabinoids, with users experiencing significantly more psychological and cardiac adverse effects.
Synthetic cannabinoid JWH-018 caused significant sperm damage and reduced testosterone in rats within days, but spermatogenesis showed partial recovery 45 days after stopping.
Controlled trial in 24 healthy people found a moderate dose of synthetic cannabinoid JWH-018 caused psychedelic effects, dissociation, amnesia, and confusion.
Case report of synthetic cannabinoid user with coumarin contamination causing severe blood clotting disorder, diagnosed rapidly via factor level testing.
Mouse study found four synthetic cannabinoids caused convulsions that were not true brain seizures on EEG, suggesting standard anti-seizure drugs like diazepam may be ineffective.
A 32-year-old man developed progressive bilateral vision loss and unusual black optic disc pigmentation after two years of synthetic cannabinoid (bonsai) use, a previously unreported finding.
A 34-year-old man developed life-threatening lung bleeding (diffuse alveolar hemorrhage) after smoking K2/Spice synthetic cannabis, successfully treated with IV steroids.
Patient on buprenorphine treatment presented with psychiatric symptoms from K2 use, but standard drug screens missed the synthetic cannabinoids and cathinones, requiring advanced GC-MS testing.
Mouse study found 7 days of synthetic cannabinoid JWH-018 produced psychotic-like symptoms and lasting brain changes in memory, social behavior, and neuroplasticity persisting 15+ days after stopping.
Mouse study found synthetic cannabinoid WIN 55,212-2 caused lasting brain metabolism reductions and memory deficits that persisted after prolonged abstinence, especially when exposure occurred in early adulthood.
Systematic review of 64 studies found synthetic cannabinoids (K2/Spice) caused more severe toxicity than THC, with 14 studies reporting deaths and seizures as common symptoms.
Synthetic cannabinoid WIN55,212-2 caused anxiety and reduced activity in mice dose-dependently, with female mice less affected.
A product sold as air freshener in Italy contained 8.5 mg of the potent synthetic cannabinoid 5F-Cumyl-PINACA, causing ER visits for hallucinations, tachycardia, and breathing difficulty.
Among 62 first-episode psychosis patients, synthetic cannabinoid users showed worse symptoms, slower recovery, and higher aberrant salience than THC users or non-users.
Among 61 first-episode psychosis patients followed for 9 months, synthetic cannabinoid users had worse symptoms, more suicidal ideation, and poorer recovery than THC users or non-users.
Systematic review of 30 human studies found cannabinoids can cause psychiatric, cognitive, and neurological brain damage, with synthetic cannabinoids posing the greatest risk.
Fatal overdose case involving two potent synthetic cannabinoids, MDMB-4en-PINACA and 4F-ABUTINACA, in a 26-year-old male. Autopsy showed acute cardiac damage.
Mouse study showed the synthetic cannabinoid AB-FUBINACA damaged hippocampal cells and impaired memory through oxidative stress, inflammation, and reduced BDNF and NMDA receptor expression.
Review documented how synthetic cannabinoids damage the brain, heart, kidneys, and liver through cannabinoid receptor overactivation and non-cannabinoid targets, far exceeding natural cannabis toxicity.
Study of 80 adolescents found half used synthetic marijuana alongside natural, primarily to save money and avoid drug tests, with dual users showing more behavioral problems.
Mouse study found neither THC nor synthetic cannabinoid JWH-073 killed heart cells, but JWH-073 caused significantly greater blood vessel relaxation, offering a potential mechanism for cardiovascular events seen with K2/Spice products.
US poison center reports for delta-8, delta-10, and THC-O acetate nearly doubled from 2021 to 2022, reaching 5,022 cases. Children under 6 made up 30% of cases, and 38% had serious outcomes.
Female mice showed greater initial impairment from synthetic cannabinoid AKB48 with higher blood levels and CB1 receptor density, while both sexes developed tolerance by the third dose, with females showing faster brain receptor adaptation.
A negative allosteric modulator of the CB1 receptor reversed synthetic cannabinoid effects in mice even after exposure, without triggering withdrawal, offering a potential first antidote for cannabinoid overdose.
Internet survey found 62 websites selling 128 synthetic cannabinoid vaping brands with misleading safety claims, bulk discounts, and easy accessibility on the regular web.
A case series of 18 incarcerated individuals found drug-soaked paper strips contained synthetic cannabinoids and opioids, causing severe CNS depression, bradycardia, and one death.
Review finds natural cannabinoids may protect kidneys through CB2 activation and help prevent stones, while synthetic cannabinoids pose serious acute kidney injury risk.
Three synthetic cannabinoids caused prolonged anxiety, motor disruption, and endocannabinoid system dysregulation in mice, with one also impairing memory.
Low-dose JWH-018 for two weeks caused persistent cardiovascular effects, cardiac lesions, mitochondrial dysfunction, and multi-organ damage in rats that worsened after discontinuation.
US military crime lab found synthetic cannabinoids in 90% of seized "blue lotus" and "valerian root" vaping products, with 65 related toxicology cases.
Two Australian cases of opioid toxicity from THC vape products containing the potent synthetic opioid protonitazene, including one death, highlight a dangerous new contamination threat.
Mouse study found synthetic cannabinoid AMB-FUBINACA toxicity was CB1-dependent, worsened by the party drug pFPP, and partially treatable with the CB1 antagonist rimonabant.
Data from 24 European countries shows synthetic cannabinoids cause more neurological emergencies (coma, seizures) while natural cannabis is linked to cardiovascular symptoms (tachycardia, chest pain).
Review warns that the 2018 Farm Bill enabled an unregulated market for CBD-derived synthetic cannabinoids, including compounds more potent than THC and acetate esters linked to lung injuries.
34 severe poisonings in New Jersey linked to gas station tianeptine products adulterated with synthetic cannabinoids. 43% required intubation.
Synthetic cannabinoids found in vapes at 78% of 27 English secondary schools tested, with prevalence tied to socioeconomic deprivation.
Seven disposable vapes sold as cannabis in the UK all contained synthetic cannabinoid 5F-MDMB-PICA at 0.85 mg/mL median, with zero natural cannabinoids.
Three novel semisynthetic THC analogs found in European products marketed as "CB9," "tresconol," and "CBx." No safety data exists for any of them.
Year-long monitoring of synthetic cannabinoids in Mayotte identified 13 different compounds across 195 street samples, revealing a market that consolidated under dominant suppliers but whose specific products changed dramatically between monthly campaigns.
A review of four years since China's 2021 synthetic cannabinoid ban documents at least six chemical strategies manufacturers use to evade the legislation, including a DIY synthesis approach that converts legal precursors into potent banned compounds.
A patient with suspected K2 overdose repeatedly improved with naloxone despite negative opioid and synthetic cannabinoid screens, highlighting the limitations of current toxicology testing and the potential value of naloxone in undifferentiated overdose.
A rat study found the synthetic cannabinoid CUMYL-4CN-BINACA caused dose-dependent oxidative damage, inflammation, and cell death in both brain and testicular tissue after just 14 days.
French poison centers recorded 304 cases of synthetic cannabinoid 5F-AKB48, mostly in teenage males vaping the drug, with 4% experiencing seizures or coma.
Mouse study found synthetic cannabinoids combined with fentanyl worsened respiratory depression and made naloxone rescue less effective, explaining some naloxone-resistant overdoses.
4F-MDMB-BUTICA caused mortality, deformities, behavioral changes, and gene expression alterations in zebrafish embryos.
Lab study found two common synthetic cannabinoids promoted nerve cell growth through CB1 receptors while simultaneously damaging mitochondria, raising concerns about neurodevelopmental effects.
Lab testing of 28 synthetic cannabinoids finds most are potent full agonists unlike THC, with unpredictable pharmacological behavior that defies simple structure-activity predictions.
JWH-018, a synthetic cannabinoid, caused arrhythmias, ischemic damage, and heart attack-like tissue changes in rats, with effects worsening at higher doses and longer exposure.
Survey of 229 cannabis users found 44.5% had used semi-synthetic cannabinoids like Delta-8 THC and THCP, with adverse effects reported across all product types.
Mouse study showed combining alcohol with synthetic cannabinoids produced worse cardiac dysfunction than either alone, reversible by blocking CB1 receptors.
Comprehensive review finds cannabis use linked to heart rhythm disturbances, especially atrial fibrillation in young males, with synthetic cannabinoids posing even higher risk.
Systematic review of 49 studies found synthetic cannabinoids cause far more severe neurological and cardiovascular complications than cannabis, with seizures, altered consciousness, and cardiac symptoms being most common.
Seven patients, mostly teens, were hospitalized with agitation and psychosis after vaping products contaminated with the synthetic cannabinoid MDMB-4en-PINACA.
A man experienced nine days of cognitive impairment after eating cookies containing HHC-C9, a semisynthetic cannabinoid sold legally as a "cannabis alternative."
Systematic review of 85 studies found synthetic cannabinoids carry 4-5x higher psychosis risk than cannabis, with a distinct clinical syndrome termed "spiceophrenia."
Systematic review of 11 case reports found synthetic cannabinoid withdrawal produced psychosis (82%), seizures (45%), and other severe symptoms within 24-48 hours, far exceeding the severity of natural cannabis withdrawal.
A 27-year-old was unknowingly exposed to the synthetic cannabinoid ADB-BUTINACA through a contaminated e-cigarette, detected only through advanced mass spectrometry after standard drug tests came back negative.
A healthy 32-year-old had a heart attack requiring emergency stent placement after smoking synthetic cannabinoid Mojo.
Synthetic cannabinoids reduced inflammation in prefrontal cortex but increased it in hippocampus, with withdrawal triggering further changes.
Clinical review outlining how emergency departments should diagnose and manage cannabis-related emergencies, distinguishing between natural and synthetic cannabinoid presentations.
Over 30 semi-synthetic cannabinoids derived from hemp CBD are circulating in Europe with unknown safety profiles, posing challenges for regulation and detection.
One ED case: a “THC” gummy was analytically confirmed as HHC, with dissociative-like symptoms.
National data from 27,482 adolescents shows synthetic cannabinoid users have 48% higher odds of sports concussion, supporting SC screening at sports physicals.
202 emergency presentations for synthetic cannabinoid MDMB-4en-PINACA: 81% unconscious, 30% seizures, 4 deaths, mostly homeless men.
Systematic review reveals smoking synthetic cannabinoids creates unknown toxic chemicals with brain-damaging potential, with only 9 studies ever investigating these breakdown products.
Rodent testing of 11 DEA-flagged synthetic cannabinoids found most significantly more potent than THC, with indazole and indole classes showing the highest potency.
British pharmacology consensus guidelines found no approved medications for cannabis or synthetic cannabinoid dependence — a major gap compared to alcohol, opioid, and nicotine treatment.
Cell-based screening detected synthetic cannabinoid activity in 6 of 23 vape liquids faster and cheaper than chemical analysis, and flagged unexpected CB1-interfering substances in five others.
Synthetic cannabinoid increased BDNF expression in adolescent rat prefrontal cortex, hippocampus, and cerebellum — potentially disrupting precisely timed brain development.
A 32-year-old died from 4F-MDMB-BICA, a synthetic cannabinoid up to hundreds of times more potent than marijuana, with coronary disease as a contributing factor.